Stock Events

Stock Events

Bellerophon Therapeutics 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other serious diseases, competing in the broader biotech space for respiratory treatments.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, competing in the development of treatments for serious conditions.
Insmed
INSM
Mkt Cap25.89B
Insmed incorporates therapies for rare diseases, including lung diseases, directly competing with Bellerophon's focus on pulmonary hypertension.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap11.99B
Arrowhead Pharmaceuticals develops medicines for intractable diseases by silencing the genes that cause them, competing in the genetic therapy space relevant to Bellerophon's interests.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the area of genetic medicine, relevant to Bellerophon's therapeutic approaches.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing in the development of novel RNA-based treatments for various diseases.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the genetic therapy market.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is focused on the development of gene-based medicines, directly competing in the innovative genetic therapy space, which includes treatments for lung and other serious diseases.

About

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Show more...
CEO
Mr. Peter Fernandes M. Pharm
Employees
20
Country
United States
ISIN
US0787711029
WKN
000A2PZZR

Listings

MU
DE
6L7A.MU
STU
DE
6L7.STU

0 Comments

Share your thoughts

FAQ

What is Bellerophon Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Bellerophon Therapeutics stocks are traded under the ticker 6L7.STU.
How many employees does Bellerophon Therapeutics have?▼
As of September 04, 2026, the company has 20 employees.
In which sector is Bellerophon Therapeutics located?▼
Bellerophon Therapeutics operates in the Health & Wellness sector.
When did Bellerophon Therapeutics complete a stock split?▼
The last stock split for Bellerophon Therapeutics was on February 11, 2020 with a ratio of 1:15.
Where is Bellerophon Therapeutics headquartered?▼
Bellerophon Therapeutics is headquartered in Warren, United States.